GUEST COLUMNISTS

• Long-Distance Rare Disease Trials: Why PLL Landed On Australia And New Zealand

  Australia and New Zealand had a lot to offer PLL Therapeutics, but speed and savings aren't the only upsides for running its rare disease trial from its European home.

• Is Moving From One-Off Solutions To A Technology Platform The Best Fit For Your R&D?

  Integrated technology platforms can connect R&D data, accelerate trials, strengthen quality, and cut costs — but successful adoption requires more than AI.

• How Digital Twins Are Reshaping Clinical R&D

  Discover how digital twins are helping predict outcomes, streamline recruitment, reduce patient burden, and accelerate clinical development.

• Why Are We Still Talking About Compensating Research Participants?

  Should we be compensating research participants? And is that even a question worth asking? Lindsay McNair, MD, and Ken Getz say yes despite recent data that doesn't point to a clear ROI.

• Examining The Potential Of P-tau217 To Provide Earlier Diagnosis Of Alzheimer's

  P-tau217 blood tests could accelerate Alzheimer’s diagnosis. Lilly’s Nino Sireci, MD, MSc, explains the research, evidence thus far, potential clinical use, and next steps.

• The 50-Page Monitoring Report And The Illusion Of Control

  A massive decentralized trial showed why more monitoring doesn’t always mean more control — and how risk-based oversight can reveal what truly matters.

• Autoimmune Drugs For Women: What To Bring To The Clinic

  Autoimmune disease is one of the most sex-skewed categories in medicine. Sex, reproductive status, and hormonal state should not be treated as background noise. 

• The Real Cost Of Sites Working Without An Enforceable Agreement: Why Your Site's Quality Of Earnings Is Suspect

  Starting site work before an enforceable agreement may look like flexibility, but it can drain leverage, create unrecoverable costs, and raise financial reporting and GCP concerns.